SLC5A2 and diabetes mellitus: Advances in continuous glucose monitoring, automated insulin delivery systems, and the availability of new agents such as SGLT2 inhibitors and GLP-1 receptor agonists have markedly improved glycaemic profiles and cardiovascular risk in patients with diabetes after kidney transplantation.